@article{oai:hama-med.repo.nii.ac.jp:00003721,
 author = {Sugimoto, Ken and Ikeya, Kentaro and Bamba, Shigeki and Andoh, Akira and Yamasaki, Hiroshi and Mitsuyama, Keiichi and Nasuno, Masanao and Tanaka, Hiroki and Matsuura, Ai and Kato, Masaichi and Ishida, Natsuki and Tamura, Satoshi and Takano, Ryosuke and Tani, Shinya and Osawa, Satoshi and Nishihira, Jun and Hanai, Hiroyuki},
 issue = {12},
 journal = {Journal of Crohn's and Colitis},
 month = {Dec},
 note = {Background & Aims: The new curcumin derivative Theracurmin? has a 27-fold higher absorption rate than natural curcumin powder. Theracurmin? is an inhibitor of nuclear factor-κB, which mediates the expression of inflammatory cytokines. The effect of Theracurmin? on inflammatory bowel disease in humans has not been explored; therefore, we investigated the efficacy and safety of Theracurmin? in patients with Crohn’s disease.
Methods: In this randomized, double-blinded study performed at 5 independent medical centers in Japan, Theracurmin? (360 mg/day, n=20) or placebo (n=10) was administered to patients with active mild-to-moderate Crohn’s disease for 12 weeks. The agent’s efficacy was assessed by evaluating clinical and endoscopic remission, healing of anal lesions, and blood levels of inflammatory markers.
Results: In the Theracurmin? group, a significant reduction in clinical disease activity was observed in week 12 relative to that in week 0 (P=0.005). On intention-to-treat analysis, clinical remission rate were 35%, 40%, and 40% at weeks 4, 8, and 12, respectively, which were significantly higher than those in the placebo group (all 0%; P=0.033, P=0.020, and P=0.020, respectively). Furthermore, reduction in endoscopic Crohn’s disease severity (P=0.032) was observed at week 12 in the Theracurmin? group. The endoscopic remission rates were 15% and 0% in the Theracurmin? and placebo groups, respectively. Significant healing of anal lesions (P=0.017) was observed at week 8 in the Theracurmin? group. No serious adverse events were observed in either group throughout the study.
Conclusions: Theracurmin? shows significant clinical and endoscopic efficacy together with afavorable safety profile in patients with active mild-to-moderate Crohn’s disease.},
 pages = {1693--1701},
 title = {Highly bioavailable curcumin derivative ameliorates Crohn’s disease symptoms: A randomized, double-blind, multicenter study},
 volume = {14},
 year = {2020}
}